April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Global Prevalence of Diabetic Retinopathy: Pooled Data from Population Studies from the United States, Australia, Europe and Asia
Author Affiliations & Notes
  • Tien Y. Wong
    Singapore Eye Research Institute, Singapore National Eye Centre, National University of Singapore, Singapore, Singapore
    Centre for Eye Research Australia, University of Melbourne, Melbourne, Australia
  • Joanne Yau
    Centre for Eye Research Australia, University of Melbourne, Melbourne, Australia
  • Sophie Rogers
    Centre for Eye Research Australia, University of Melbourne, Melbourne, Australia
  • Ryo Kawasaki
    Centre for Eye Research Australia, University of Melbourne, Melbourne, Australia
  • Ecosse L. Lamoureux
    Centre for Eye Research Australia, University of Melbourne, Melbourne, Australia
  • Meta-Eye Group
    Singapore Eye Research Institute, Singapore National Eye Centre, National University of Singapore, Singapore, Singapore
  • Jonathan Kowalski
    Glbl Hlth Outcomes Strat Res, Allergan, Inc, Irvine, California
  • Footnotes
    Commercial Relationships  Tien Y. Wong, Allergan, Bayer, Novartis, Pfizer, Solvay (R, C); Joanne Yau, None; Sophie Rogers, None; Ryo Kawasaki, None; Ecosse L. Lamoureux, None; Jonathan Kowalski, Allergan (E)
  • Footnotes
    Support  Allergan Pty Ltd; National Health & Medical Research Council Centres for Clinical Research Excellence (CCRE), Australia; National Medical Research Council, (NMRC/STaR/0003/2008), Singapore
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4818. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tien Y. Wong, Joanne Yau, Sophie Rogers, Ryo Kawasaki, Ecosse L. Lamoureux, Meta-Eye Group, Jonathan Kowalski; Global Prevalence of Diabetic Retinopathy: Pooled Data from Population Studies from the United States, Australia, Europe and Asia. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4818.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To estimate the global prevalence of any diabetic retinopathy (DR), proliferative diabetic retinopathy (PDR), diabetic macular edema (DME) and vision-threatening diabetic retinopathy (VTDR) (defined as PDR and/or DME) based on pooled data from studies in the United States, Australia, Europe and Asia.

Methods: : Population-based studies of general or diabetic populations where DR status was ascertained from fundus photography were invited for collaboration. Studies provided individual participant data regarding any DR, PDR, DME, age, gender, ethnicity and other risk factors. Pooled prevalence was directly age-sex-standardized to the 2010 world diabetes population (age 20-79 years)

Results: : A total of 35 studies provided data from 22,896 diabetic subjects aged from 3 to 97 years. Median duration of diabetes was 7.8 years and mean HbA1C was 8.5%. Based on our analysis of high quality studies only, the age-standardized prevalence was 35.36% (95% confidence interval [CI] 35.17-35.56%) for any DR, 7.24% (CI: 7.15-7.33%) for PDR, 7.48% (CI: 7.39-7.57%) for DME and 11.72% (CI: 11.61-11.83%) for VTDR. Prevalence of VTDR was markedly higher in people with type 1 diabetes than type 2 (38.5% vs. 6.92%), and increased with diabetes duration (3.78% in persons with diabetes for <10 years to 31.0% in those with 20+ years’ duration), increasing levels of HbA1C (5.4% for HbA1c ≤7.0% vs. 18.35% for HbA1C >9.0%), and blood pressure (7.6% vs. 17.63% in non-hypertensive vs. hypertensive individuals respectively).

Conclusions: : Our study estimates that in 2010 (2030), globally, there are approximately 100.8 (154.9) million people with DR, 20.6 (31.7) million with PDR, 21.3 (32.8) million with DME and 33.4 (51.3) million with VTDR. Diabetes duration, poorer glycemic and blood pressure control are strongly associated with a higher prevalence of these endpoints. These data highlight the substantial public health impact of diabetes.

Keywords: diabetic retinopathy • clinical (human) or epidemiologic studies: prevalence/incidence • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×